GT Biopharma Inc
GTBP
查看详细走势图
0.410USD
+0.001+0.24%
交易中 （美东）报价延迟15分钟
3.22总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.24%
5天
-10.91%
1月
-14.25%
6月
-29.33%
今年开始到现在
-47.80%
1年
-82.92%
查看详细走势图
TradingKey GT Biopharma Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
GT Biopharma Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名179/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价3.00。中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
GT Biopharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
GT Biopharma Inc亮点
亮点风险
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值合理
公司最新PE估值-0.07，处于3年历史合理位
机构减仓
最新机构持股815.08K股，环比减少45.12%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值0.00
分析师目标
根据
1
位分析师
买入
评级
3.000
目标均价
+572.65%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
GT Biopharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
GT Biopharma Inc简介
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
公司代码GTBP
公司GT Biopharma Inc
CEOBreen (Michael)
网址https://www.gtbiopharma.com/
相关品种
